title: Strontium-89 therapy for the treatment of huge osseous metastases in prostate carcinoma: A case report.
abstract: Prostate cancer is a growing public health problem. The palliation of pain in patients with painful bone metastases is of primary importance in the clinical management of advanced cancer. Internal therapy with radionuclides, which concentrate at sites of increased bone turnover, is used to control pain and improve quality of life as an alternative to conventional therapies. In the present study, we report the case of a 52-year-old male who had been diagnosed with prostate cancer. The patient presented with severe pain in multiple areas, but particularly in the right hip. A whole-body bone scan revealed that the right hip, ilium and ischium were covered with huge metastatic lesions. Treatment with radionuclide strontium-89 chloride ((89)Sr) resulted in a partial response which was confirmed by the successful relief of pain and other imaging modalities. No significant change in the leukocyte or thrombocyte levels was observed. The results of the present study indicate that systemic radionuclide therapy using (89)Sr is an effective, well-tolerated and safe palliative treatment in patients with huge osseous metastases in prostate carcinoma.
authors: Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041,  P.R. China.
authors: Wenjie
authors: W
authors: Zhang
authors: Weiwei
authors: W
authors: Zhao
authors: Zhiyun
authors: Z
authors: Jia
authors: Houfu
authors: H
authors: Deng
keywords: huge osseous metastases; nuclear medicine; radionuclide; strontium-89
references: J Natl Med Assoc. 2007 Jul;99(7):785-94
references: 17668645
references: Radiat Environ Biophys. 2008 Apr;47(2):225-39
references: 18204850
references: Cancer. 1993 Dec 1;72(11 Suppl):3433-5
references: 8242575
references: Oncol Rep. 2003 Mar-Apr;10(2):399-404
references: 12579279
references: Cochrane Database Syst Rev. 2000;(2):CD001793
references: 10796822
references: Eur Urol. 2008 Jan;53(1):68-80
references: 17920184
references: Curr Opin Oncol. 2007 Jul;19(4):308-14
references: 17545792
references: Q J Nucl Med. 2001 Mar;45(1):78-83
references: 11456379
references: Urology. 1983 Apr;21(4):337-44
references: 6340324
references: Radiother Oncol. 2005 Jun;75(3):258-70
references: 16299924
references: Eur J Oncol Nurs. 2007;11  Suppl 2:S32-7
references: 17804294
references: Am J Health Syst Pharm. 1995 Oct 15;52(20):2189-95
references: 8564588
references: Nucl Med Commun. 1995 Jun;16(6):452-6
references: 7675358
references: Eur J Nucl Med. 1986;12(9):447-54
references: 3102236
references: Drug Des Devel Ther. 2009 Sep 21;3:27-40
references: 19920919
references: Oncologist. 2003;8(2):161-73
references: 12697941
references: Lancet Oncol. 2005 Jun;6(6):392-400
references: 15925817
references: Clin Oncol (R Coll Radiol). 1992 Mar;4(2):101-7
references: 1372817